# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 05-13-2024 | 03-31-2024 | 10-Q | |
2 | 03-05-2024 | 12-31-2023 | 10-K | |
3 | 11-13-2023 | 09-30-2023 | 10-Q | |
4 | 08-28-2023 | 06-30-2023 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of ap...
Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the trea...
B of A Securities analyst Geoff Meacham initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and announ...
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum a...
The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting unde...
Jefferies analyst Akash Tewari maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target from $37 t...
Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for...